A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants

NCT03618160 | Terminated Phase 1

• 2 other identifiers: CR10849764565111NAS1001
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64565111 following single and multiple subcutaneous (SC) doses in healthy Japanese male participants.

Conditions

Healthy

Outcome Measures

Primary Outcomes (18)

• Part 1 and Part 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability

  An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.

  Up to Day 35

• Part 1: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111

  Cmax is defined as the maximum observed serum concentration.

  Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

• Part 1: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111

  Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.

  Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

• Part 1: Area Under Serum Concentration Curve From Time 0 to Time of the Last Measurable Concentration (AUC[0-Last]) of JNJ-64565111

  AUC(0-Last) is defined as the AUC from time 0 to the time of the last measurable (non-below quantification limit \[non-BQL\]) serum concentration.

  Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

• Part 1: Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC[0-Infinity]) of JNJ-64565111

  AUC (0-infinity) is defined as the area under the serum concentration-time curve from time zero to infinite time calculated as the sum of AUC(0-last) and Clast/ lambda (z); wherein AUC(0-last) is area under the serum concentration time curve from time zero to last measurable serum concentration, Clast is the last observed measurable (non-BQL) serum concentration, and lambda (z) is the apparent terminal elimination rate constant.

  Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

• Part 1: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111

  t1/2 is defined as the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).

  Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

• Part 1: Apparent Volume of Distribution (V/F) of JNJ-64565111

  V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)\*AUC\[0-infinity\]).

  Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

• Part 1: Total Apparent Clearance (CL/F) of JNJ-64565111

  CL/F is defined as the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUC\[0-infinity\].

  Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose

• Part 2: Number of Participants With AEs as a Measure of Safety and Tolerability

  An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.

  Up to Day 72

• Part 2: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111

  Cmax is defined as the maximum observed serum concentration.

  Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

• Part 2: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111

  Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.

  Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

• Part 2: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111

  t1/2 is defined as the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).

  Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

• Part 2: Apparent Volume of Distribution (V/F) of JNJ-64565111

  V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)\*AUCtau).

  Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

• Part 2: Total Apparent Clearance (CL/F) of JNJ-64565111

  CL/F is the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUCtau.

  Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

• Part 2: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-64565111

  AUCtau is defined as the measure of the serum drug concentration from time zero to end of dosing interval.

  Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: 72, 96, 144, 168 hours postdose

• Part 2: Observed Serum Concentration Just Prior to the Beginning or the End of a Dosing Interval (Ctrough) of JNJ-64565111

  Ctrough is defined as the observed serum concentration just prior to the beginning or the end of a dosing interval.

  Day 8: Predose ; Day 15: Predose; Day 22: Predose, 168 hours postdose

• Part 2: Average Concentration Over the Dosing Interval Tau (T) at Steady State (Caverage,ss) of JNJ-64565111

  Caverage,ss is defined as area under the serum concentration time curve observed during a dosing interval (tau) at steady state) will be calculated as AUCtau/Tau.

  Day 22: Predose, 72, 96, 144, 168 hours postdose

• Part 2: Observed Accumulation Index (AR-AUC) of JNJ-64565111

  AR-AUC is determined after multiple dose administration of JNJ-64565111 and calculated by using the equation: AUCtau, Day 22 divided by AUCtau, Day 1.

  Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose

Secondary Outcomes (26)

• Part 1 and 3: Number of Participants With Anti-Drug Antibodies (ADAs) to JNJ-64565111

  Predose, 144 and 816 hours postdose

• Part 1 and Part 3: Change From Baseline in Body Weight

  Baseline to Day 35

• Part 1 and Part 3: Change from Baseline in Fasting Plasma Glucose (FPG) Levels

  Baseline to Day 35

• Part 1 and Part 3: Change From Baseline in Total Cholesterol

  Baseline to Day 35

• Part 1 and Part 3: Change From Baseline in Low Density Lipoprotein- Cholesterol (LDL-C)

  Baseline to Day 35

Study Arms (3)

Part 1: SAD (Cohort 1 to 3)

EXPERIMENTAL

Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.

Drug: JNJ-64565111; Drug: Placebo

Part 2: MAD (Cohort 4 to 6)

EXPERIMENTAL

Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.

Drug: JNJ-64565111; Drug: Placebo

Part 3: Single Dose (Cohort 7)

EXPERIMENTAL

Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.

Drug: JNJ-64565111

Interventions

JNJ-64565111 DRUG

Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.

Part 1: SAD (Cohort 1 to 3); Part 2: MAD (Cohort 4 to 6); Part 3: Single Dose (Cohort 7)

Placebo DRUG

Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.

Part 1: SAD (Cohort 1 to 3); Part 2: MAD (Cohort 4 to 6)

Eligibility Criteria

• Age: 20 Years - 65 Years
• Gender Eligibility Details: The main reason to enroll male participants in this study is to decrease operational difficulties at site level as there is no specific reason to enroll female participants.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• For Part 1 and Part 2, participant must be a Japanese male 20 to 65 years of age, inclusive, at the time of informed consent for screening. For Part 3, participant must be a Caucasian male (defined as white and all of his parents and grandparents are white as determined by participant's verbal report) 20 to 65 years of age, inclusive, at the time of informed consent for screening
• Participant must agree to use an adequate contraception method as deemed appropriate by the investigator; to always use a condom during sexual intercourse (even in case of prior vasectomy), or to remain abstinent, and not to donate sperm during the study and for 90 days after study drug administration. Participants should encourage their female partner to use an effective method of contraception (example, prescription oral contraceptives, contraceptive injections, intrauterine device, or contraceptive patch) in addition to the condom used by the male study participant
• Participant must have a body mass index (BMI) ranging from 25 to 40 kilogram per meter square (kg/m\^2), weighing 120 kilogram (kg) or less
• Participant must be healthy on the basis of physical examination, medical history, vital signs, and 12 lead electrocardiogram (ECG) performed at screening

You may not qualify if:

• Participant having a history of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiovascular disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), significant pulmonary disease, including bronchospastic respiratory disease, hepatic or renal insufficiency, type 1 diabetes mellitus, type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study result
• Participant has taken any prescription or nonprescription medication (including vitamins and herbal supplements), except for acetaminophen, from 14 days before the first dose of the study drug is scheduled until completion of the study
• Participant has received an experimental drug (including investigational vaccines) or used an experimental medical device within 3 months or within a period less than 5 times the drug's half life, whichever is longer, prior to screening
• Participant test positive for human immunodeficiency virus (HIV \[positive serology for HIV antigen/antibody\]), tests positive for hepatitis B virus surface antigen, or has antibodies to hepatitis C virus (HCV) at screening
• Participant has had major surgery (example, requiring general anesthesia) within 4 months before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 6 months after study drug administration

Sponsors & Collaborators

• Janssen Pharmaceutical K.K.: lead

Study Sites (2)

Souseikai Hakata Clinic

Fukuoka, 812-0025, Japan

Location

Sumida Hospital

Tokyo, 130-0004, Japan

Location

Study Officials

• Janssen Pharmaceutical K.K Clinical Trial

  Janssen Pharmaceutical K.K.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 2, 2018
• First Posted: August 7, 2018
• Study Start: August 6, 2018
• Primary Completion: June 21, 2019
• Study Completion: June 21, 2019
• Last Updated: February 3, 2025

Record last verified: 2025-01

Locations

JP (2)